Please assess the completion status of the following clinical trial:

Trial Title: Pre-Prostatectomy Lovastatin on Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adenocarcinoma of the prostate, without evidence of spread beyond to lymph nodes, bone, or visceral organs, stage T1c or higher.~2. Tumor Gleason sum of 7 (4+3 and 3+4 allowed) in at least one core, after central review of prostate biopsy at Johns Hopkins. However, in accordance with standard clinical practices, adenocarcinoma must be present in at least two discrete biopsy sections ( may vary in Gleason score).~3. Age ≥18 years of age.~4. Radical prostatectomy scheduled at Johns Hopkins.~5. Willingness to sign and ability to understand informed consent.~6. No history of treatment with any statin-class medication within 6 months of entry into the trial.~7. ECOG (Eastern Cooperative Oncology Group) performance status 0-1.~8. Adequate bone marrow, hepatic, and renal function as determined by:~WBC (white blood cells) \>3,500 cells/mm3 ANC (absolute neutrophil count) \>1,500 cells/mm3 Hemoglobin \>9 g/dl Platelet count \>100,000 cells/mm3 Serum creatinine \< 2.6 mg/dl Serum bilirubin \<2 mg/dl ALT (alanine aminotransferase), AST (aspartate aminotransferase), and Alkaline Phosphatase \<2 times the upper limit of normal Triglycerides and total cholesterol \<3 times the upper limit of normal~Exclusion Criteria:~1. Patients with evidence of metastatic prostate cancer, including bone, visceral, brain, and lymph node metastases.~2. Other histologic prostate cancers, including ductal, sarcomatous, lymphoma, small cell, and neuroendocrine tumors.~3. Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy including active liver disease, unexplained persistent elevation of serum transaminases, or medications that interfere with the metabolism of lovastatin, or gastrointestinal disease that would limit the ability to swallow or take oral medications or absorb them.~4. Concurrent malignancy other than prostate cancer.~5. Inability to provide informed consent.~6. Concomitant use of azole antifungals, cyclosporine, clarithromycin, erythromycin, fibric acid derivatives, lopinavir/ritonavir, niacin, ritonavir/saquinavir~7. Prior chemotherapy, radiation therapy, biologic therapy, or immunotherapy for prostate cancer.~8. Poor performance status (ECOG \>1).~9. Prostatectomy at other hospital other than Johns Hopkins.~10. Prior history of allergy or severe reaction to statins or statin derivatives.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Lovastatin (Type: EXPERIMENTAL): After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy